文献速递生殖医学

线粒体置换技术解决线粒体功能障碍与卵胞质缺陷:现状如何?

Mitochondrial replacement techniques to resolve mitochondrial dysfunction and ooplasmic deficiencies: where are we now?
PubMed 文献 · Hum Reprod · 2025-01-01

线粒体在卵母细胞能力、受精和早期胚胎发育中起关键作用,母源线粒体DNA突变可导致严重疾病并影响卵巢衰老和女性不育。线粒体置换技术(MRT)分为异体与自体两类,异体方法包括生发泡、原核、母源纺锤体和极体转移,但存在伦理与异质性担忧;自体方法中AUGMENT经随机临床试验显示较常规IVF无显著获益。综述认为这些技术结果有前景,但需进一步随机临床试验确立有效性与安全性。

要点

  • 异体MRT包括生发泡、原核、母源纺锤体和极体转移,存在第三方遗传物质继承与异质性伦理担忧。
  • AUGMENT经随机临床试验显示较常规IVF无显著获益,其疗效存在争议。
  • 基于自体非侵入性干细胞的近期方法结果有前景,但需进一步随机临床试验确立临床有效性与安全性。

核心结论

  • 综述认为,这些技术结果有前景,但需进一步随机临床试验确立其临床有效性与安全性;只有获得稳健证据后,MRT才可能成为克服不育并让患者获得遗传相关胚胎的可行治疗选择。

研究设计与样本

  • 本文为综述,旨在概述MRT在解决线粒体功能障碍所致卵母细胞质量低下方面的现状。
  • 原文未报告检索范围。

主要发现

  • 异体方法将健康供体线粒体转移至受体卵母细胞,包括生发泡、原核、母源纺锤体和极体转移。
  • 自体方法中,AUGMENT从患者分离卵原前体细胞、提取其线粒体并在ICSI时注射,但随机临床试验显示较常规IVF无显著获益。

关键数值与推荐

  • 原文未报告关键数值与推荐条款。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需进一步随机临床试验确立这些技术的有效性与安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mitochondria are the powerhouses of cell and play crucial roles in proper oocyte competence, fertilization, and early embryo development. Maternally inherited mitochondrial DNA (mtDNA) mutations can have serious implications for individuals, leading to life-threatening disorders and contribute to ovarian ageing and female infertility due to poor oocyte quality. Mitochondrial replacement techniques (MRTs) have emerged as a promising approach not only to replace defective maternal mitochondria in patients carrying mtDNA mutations, but also to enhance oocyte quality and optimize IVF outcomes for individuals experiencing infertility. There are two main categories of MRT based on the source of mitochondria. In the heterologous approach, mitochondria from a healthy donor are transferred to the recipient's oocyte. This approach includes several methodologies such as germinal vesicle, pronuclear, maternal spindle, and polar body transfer. However, ethical concerns have been raised regarding the potential inheritance of third-party genetic material and the development of heteroplasmy. An alternative approach to avoid these issues is the autologous method. One promising autologous technique was the autologous germline mitochondrial energy transfer (AUGMENT), which involved isolating oogonial precursor cells from the patient, extracting their mitochondria, and then injecting them during ICSI. However, the efficacy of AUGMENT has been debated following the results of a randomized clinical trial (RCT) that demonstrated no significant benefit over conventional IVF. Recent developments have focused on novel approaches based on autologous, non-invasively derived stem cells to address infertility. While these techniques show promising results, further RCTs are necessary to establish their effectiveness and safety for clinical use. Only after robust evidence becomes available could MRT potentially become a viable treatment option for overcoming infertility and enabling patients to have genetically related embryos. This review aims to provide an overview of the current state of MRTs in addressing low oocyte quality due to mitochondrial dysfunction.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Subirá J, Soriano MJ, Del Castillo LM, et al. Mitochondrial replacement techniques to resolve mitochondrial dysfunction and ooplasmic deficiencies: where are we now? Hum Reprod. 2025. PMID: 40083121. doi:10.1093/humrep/deaf034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。